Yifan Pharmaceutical (SHE:002019) unit Hefei Yifan Biopharmaceutical secured a drug registration certificate from China's National Medical Products Administration for its famotidine injection, according to a Thursday filing on the Shenzhen Stock Exchange.
The drug is mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer, and gastric and duodenal mucosal erosion.
The pharmaceutical company is allowed to market the drug until Sept. 9, 2029, the filing added.
Price (RMB): ¥10.31, Change: ¥+0.17, Percent Change: +1.68%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.